European Journal of Clinical Pharmacology

, Volume 25, Issue 2, pp 207–210 | Cite as

Fasting and postprandial absorption of digoxin from a microencapsulated formulation

  • B. Bergdahl
  • C. Bogentoft
  • U. E. Jonsson
  • J. O. Magnusson


The absorption of digoxin from a capsule preparation containing a large number of small, enteric-coated granules of the glycoside (Preparation CR) was compared in 10 volunteers with that from a rapidly dissolving tablet (Preparation L). Plasma and urine digoxin concentrations were measured by radioimmunoassay. In the fasting state, after a loading dose of digoxin (0.76 mg), peak plasma concentrations were significantly (p<0.001) lower after CR (2.0±0.5 nmol/l, mean±SD) than L (4.7±1.1 nmol/l). Peak concentrations after CR were significantly (p<0.001) delayed compared to L (3.3±0.6 h vs 1.1±0.4 h). Also, postprandial peak plasma concentrations at steady state, were significantly (p<0.01) lower after CR (1.0±0.3 nmol/l) than L (2.7±0.5 nmol/l), and the peak concentrations occurred later (3.9±1.7 h vs 1.4±0.9 h). The area under the plasma concentration-time curves was smaller (p<0.01) for CR (17.7±5.9 nmol·l−1·h) than for L (22.4±4.1 nmol·l−1·h), and so was the amount of drug excreted in urine (174±25 µg vs 190±31 µg; p<0.005). Thus, the absorption rate of digoxin from the enteric-coated formulation was markedly reduced but at the cost of a variable reduction in the amount absorbed.

Key words

digoxin absorption enteric coating radioimmunoassay urinary digoxin plasma digoxin dissolution rate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andersson K-E, Nyberg L, Dencker H, Göthlin J (1975) Absorption of digoxin in man after oral and intrasigmoid administration. Eur J Clin Pharmacol 9: 39–47PubMedCrossRefGoogle Scholar
  2. 2.
    Aronson JK (1980) Clinical pharmacokinetics of digoxin 1980. Clin Pharmacokinet 5: 137–149PubMedCrossRefGoogle Scholar
  3. 3.
    Bertler Å, Medin S, Nyberg L, Redfors A (1972) Bioavailability of digoxin. Lancet 2: 708PubMedCrossRefGoogle Scholar
  4. 4.
    Bergdahl B, Bogentoft C, Jonsson UE, Magnusson JO (1980) Absorption of digoxin from a new microencapsulated formulation. Eur J Clin Pharmacol 17: 443–447PubMedCrossRefGoogle Scholar
  5. 5.
    Bogentoft C, Carlsson I, Ekenved E, Magnusson A (1978) Influence of food on the absorption of acetylsalicylic acid from enteric coated dosage forms. Eur J Clin Pharmacol 14: 351–355PubMedCrossRefGoogle Scholar
  6. 6.
    Gault MH, Charles JD, Sugden DL, Kepkay DC (1977) Hydrolysis of digoxin by acid. J Pharm Pharmacol 29: 27–32PubMedGoogle Scholar
  7. 7.
    Gault H, Kalra J, Ahmed M, Kepkay D, Barrowman J (1980) Influence of gastric pH on digoxin biotransformation. I. Intragastric hydrolysis. Clin Pharmacol Ther 27: 16–21PubMedCrossRefGoogle Scholar
  8. 8.
    Gerson CD, Lowe EH, Lindenbaum J (1980) Bioavailability of digoxin tablets in patients with gastrointestinal dysfunction. Am J Med 69: 43–49PubMedCrossRefGoogle Scholar
  9. 9.
    Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW (1974) Bioavailability of digoxin tablets and elexir in the fasting and postprandial states. Clin Pharmacol Ther 16: 444–448PubMedGoogle Scholar
  10. 10.
    Johnson BF, O'Grady J, Sabey GA, Bye C (1978) Effect of a standard breakfast on digoxin absorption in normal subjects. Clin Pharmacol Ther 23: 315–319PubMedGoogle Scholar
  11. 11.
    Kuhlmann J, Abshagen U, Riebrock N (1973) Cleavage of glycosidic bonds of digoxin and derivates as function of pH and time. Naunyn-Schmiedeberg's Arch Pharmacol 276: 149–156CrossRefGoogle Scholar
  12. 12.
    Lindenbaum J, Rund DG, Butler VP, Tse-Eng D, Saha JR (1981) Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med 305: 789–794PubMedCrossRefGoogle Scholar
  13. 13.
    Magnusson JO, Bergdahl B, Bogentoft C, Jonsson UE, Tekenbergs L (1982a) Excretion of digoxin and its metabolites in urine after a single oral dose in healthy subjects. Biopharm Drug Disp 3: 211–218Google Scholar
  14. 14.
    Magnusson JO, Bergdahl B, Bogentoft C, Jonsson UE (1982b) Metabolism of digoxin and absorption site. Br J Clin Pharmacol 14: 284–285PubMedGoogle Scholar
  15. 15.
    Manninen V, Reissell P, Pankkala E (1976) Transient cardiac arrhythmias after single daily maintenance doses of digoxin. Clin Pharmacol Ther 20: 266–268PubMedGoogle Scholar
  16. 16.
    Nyberg L, Bratt L, Forsgren A, Hugosson S (1974a) Bioavailability of digoxin from tablets. I. In vitro characterization of digoxin tablets. Acta Pharm Suec 11: 447–458PubMedGoogle Scholar
  17. 17.
    Nyberg L, Andersson K-E, Berler Å (1974b) Bioavailability of digoxin from tablets. III. Availability of digoxin in man from preparations with different dissolution rate. Acta Pharm Suec 11: 471–492PubMedGoogle Scholar
  18. 18.
    Osneas J-B (1978) Kardiale bivirkningar de forste timene etter digoxininntak. Tidsskr Nor Laegeforen 2: 92Google Scholar
  19. 19.
    Sanchez N, Sheiner LB, Halkin H, Melmon KL (1973) Pharmacokinetics of digoxin: Interpreting bioavailability. Br Med J 4: 132–134PubMedGoogle Scholar
  20. 20.
    Smith TW (1975) Digitalis toxicity: Epidemiology and clinical use of serum concentration measurements. Am J Med 58: 470–476PubMedCrossRefGoogle Scholar
  21. 21.
    Sterson LA, Shaffer RD (1978) Kinetics of digoxin stability in aqueous solution. J Pharm Sci 67: 327–330Google Scholar
  22. 22.
    White RJ, Chamerlain DA, Howard M, Smith TW (1971) Plasma concentrations of digoxin after oral administration in the fasting and postprandial state. Br Med J 1: 380–381PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • B. Bergdahl
    • 1
  • C. Bogentoft
    • 2
  • U. E. Jonsson
    • 2
  • J. O. Magnusson
    • 1
  1. 1.Departments of Clinical Pharmacology and Internal Medicine, Division of CardiologyUniversity HospitalLinköpingSweden
  2. 2.Department of PharmaceuticsAB HässleMölndalSweden

Personalised recommendations